Sign In
Buy CRL
$179.87
+5.08 (+2.91%)
At Close: Jun 03, 2026
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line?
07:16am, Friday, 17'th Jan 2025
Charles River and Akron Bio collaborate to boost operations by integrating CGMP materials into the Cell Therapy Platform.
Should You Retain Charles River Stock in Your Portfolio Now?
08:30am, Thursday, 02'nd Jan 2025
CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors.
FDA Gives CRL to J&J's BLA for Subcutaneous Rybrevant in NSCLC
09:25am, Tuesday, 17'th Dec 2024
The FDA issues a complete response letter to JNJ's BLA seeking approval for the subcutaneous formulation of Rybrevant in EGFR-mutated non-small cell lung cancer.
Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report?
06:49am, Monday, 09'th Dec 2024
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
CRL Stock to Gain From the Global Biotech Incubator Program Launch
09:06am, Friday, 06'th Dec 2024
Charles River's new initiative specifically caters to early-stage biotechnology developers.
Charles River Introduces Global Biotech Incubator Program
08:00am, Thursday, 05'th Dec 2024
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing
Is it the Right Time to Hold Charles River Stock in Your Portfolio?
08:21am, Thursday, 28'th Nov 2024
Investors are optimistic about CRL stock due to its strong RMS prospects and inorganic growth efforts.
Charles River (CRL) International Revenue in Focus: Trends and Expectations
10:20am, Monday, 11'th Nov 2024
Explore how Charles River's (CRL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript
06:51pm, Wednesday, 06'th Nov 2024
Charles River Laboratories International, Inc. (NYSE:CRL ) Q3 2024 Earnings Conference Call November 6, 2024 9:30 AM ET Company Participants Todd Spencer - Corporate Vice President of Investor Relatio
Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall
01:01pm, Wednesday, 06'th Nov 2024
CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment.
Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
10:35am, Wednesday, 06'th Nov 2024
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wal
Charles River Laboratories (CRL) Q3 Earnings and Revenues Beat Estimates
09:10am, Wednesday, 06'th Nov 2024
Charles River Laboratories (CRL) came out with quarterly earnings of $2.59 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.72 per share a year ago.
Charles River Laboratories raises annual profit forecast on stabilizing biotech demand
08:30am, Wednesday, 06'th Nov 2024
Charles River Laboratories raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects demand to stabilize from biotech clients f
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Wednesday, 30'th Oct 2024
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Charles River (CRL) is Poised to Beat Earnings Estimates Again
01:10pm, Tuesday, 29'th Oct 2024
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
